Heal to Feel: New Management Strategies for Neurotrophic Keratitis (CME/CE Webcast)
Activity Description and Purpose
Neurotrophic keratitis (NK) is characterized by disrupted tearing and progressive corneal damage that does not readily heal. Until very recently, a lack of effective treatment to reinnervate and heal eyes affected by NK served to further hamper efforts toward timely diagnosis. Now that an effective treatment is available, ophthalmologists and optometrists need to identify patients who might benefit from treatment before the disease progresses to the point of corneal perforation and subsequent loss of visual acuity. The desired results of this educational activity are for ophthalmologists and optometrists to have a better understanding of the pathophysiology of NK as well as current best practices for screening, diagnosis, and treatment.
This educational activity is intended for ophthalmologists and optometrists.
After completing this activity, participants will be better able to:
- Review the pathophysiologic mechanisms driving neurotrophic keratitis
- Explain the relationship between corneal innervation and ocular surface healing in neurotrophic keratitis treatment
- Integrate the evaluation of corneal sensitivity into regular assessments of ocular surface disease
- Describe clinical trial data for approved neurotrophic keratitis therapy
- Apply evidence-based treatment strategies for a variety of patients with neurotrophic keratitis
|Paul Karpecki, OD (Co-Chair)|
Director, Cornea and External Disease
Kentucky Eye Institute and Gaddie Eye Centers
|Francis S. Mah, MD (Co-Chair)|
Director, Cornea and External Diseases
Co-Director, Refractive Surgery
Scripps Clinic Torrey Pines
La Jolla, California
|Douglas K. Devries, OD |
Associate Clinical Professor
Pacific University College of Optometry
Advanced Vision and Laser Center
|Preeya K. Gupta, MD|
Associate Professor of Ophthalmology
Cornea & Refractive Surgery
Duke University Eye Center
Durham, North Carolina
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Douglas K. Devries, OD, is an advisory board member of Alcon, Allergan, Avellino Labs, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, ScienceBased Health, Shire, Sun Pharmaceutical Industries, Inc, and TearLab Corporation; is on the speakers bureau for Bio-Tissue, Johnson & Johnson Vision Care, Inc, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, ScienceBased Health, Shire, and Sun Pharmaceutical Industries, Inc, and TearLab Corporation; and has ownership interest in Bruder Healthcare.
Preeya K. Gupta, MD, is a consultant for Alcon, Allergan, Aurea Medical, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, New World Medical, Inc, NovaBay Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Ocular Science, ReGenTree, LLC, Shire, Sight Sciences, Sun Pharmaceutical Industries, Inc, TearLab Corporation, and Zeiss.
Paul Karpecki, OD, is a consultant for Aldeyra Therapeutics, Akorn, Inc, Alcon, Allergan, Allysta Pharmaceuticals, Inc, Aurinia Pharmaceuticals Inc, Avellino Labs, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, Dompé US, Inc, EyeGate, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Mallinckrodt, Novaliq GmbH Germany, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OCuSOFT Inc, SBH Sciences Inc, Sun Pharmaceutical Industries, Inc, and Tarsus; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Dompé US, Inc, Mallinckrodt, Novartis Pharmaceuticals Corporation, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Bruno Vision, Dompé US, Inc, Novartis Pharmaceuticals Corporation, and Sight Sciences; has ownership interest in Amaros, BlephEx, Cambium Medical Technologies, Cool Doctors, EnChroma, EyeBrain Medical, Eyedaptic Inc, Eyedetec Medical, Eyevance, Healthe, HuiAI, Ivantis Inc, KEPLR, LeGrande, LenTechs, Lubris Biopharma, Oyster Point Pharma, Inc, and RxSIGHT.
Francis S. Mah, MD, is a consultant for Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyenovia, Inc, EyePoint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, and Polyactiva Pty Ltd; is on the speakers bureau for Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Sun Pharmaceutical Industries, Inc; has ownership interest in Avellino Labs, iVIEW Therapeutics, Inc, Ocular Science, Okogen, and Sydnexis.
Angie E. Wen, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 1.25 CE credits for optometrists.
COPE Course ID: 68282-AS
COPE Course Category: Treatment & Management of Ocular Disease: Anterior Segment (AS)
Disclosure of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Dompé US, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 215
- 1.25 COPE
Clicking Register indicates that you have reviewed the CME/CE information for this activity.
Learning Method and Medium
This educational activity consists of a webcast and thirteen (13) study questions. The participant should, in order, read the learning objectives, complete the pretest, view the webcast, answer all questions in the post test, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.25 hours to complete.